Predictive value of serum glutathione S-transferase (GST-â), P-glycoprotein (PGP), P53, KI-67 in breast cancer: A systematic review and meta-analysis.

IF 1.5 4区医学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY

Journal of Medical Biochemistry Pub Date : 2025-08-21 DOI:10.5937/jomb0-56147

Nuan Zhang, Zhipeng Wang, Yang Zhang

{"title":"Predictive value of serum glutathione S-transferase (GST-â), P-glycoprotein (PGP), P53, KI-67 in breast cancer: A systematic review and meta-analysis.","authors":"Nuan Zhang, Zhipeng Wang, Yang Zhang","doi":"10.5937/jomb0-56147","DOIUrl":null,"url":null,"abstract":"Background: To assess the predictive value of drug-resistant proteins - serum glutathione S-transferase (GST-â), P-glycoprotein (PGP), P53, Ki-67 - in triple-negative breast cancer (TNBC) and their role in chemotherapy resistance. This systematic review and meta-analysis aimed to explore their clinical relevance for improving TNBC treatment outcomes.Methods: We systematically searched PubMed, Web of Science, CNKI, WanFang, and VIP databases for studies from 2010 to 2024. Studies meeting predefined inclusion and exclusion criteria were selected. Data extraction and quality assessment were performed by two independent researchers. Meta-analysis was conducted using RevMan 5.3 software.Results: Seven studies were included, involving 1,772 patients, with 745 TNBC cases and 1,027 non-TNBC cases. Meta-analysis showed that in TNBC compared to non-TNBC, the expression rates of GST-â [O R= 3.41, 95% CI (2.21, 5.25), P< 0.00001], PGP [O R= 1.87, 95% CI (1.17, 2.98), P= 0.008], P53 [O R= 3.65, 95% CI (2.25, 5.91), P< 0.00001], and Ki-67 [O R= 1.19, 95% CI (0.54, 1.84), P= 0.0004] were significantly elevated, indicating higher drug resistance. However, no significant differences were found in Topo I, II, or III expression. Additionally, TNBC patients had poorer disease-free survival (DFS) [O R = 0.30, 95% CI (0.15, 0.59), P=0.0005] and overall survival (OS) [O R=0.17, 95% CI (0.11, 0.28), P<0.00001] compared to non-TNBC patients.Conclusions: The elevated expression of drug-resistant proteins GST-â, PGP P53, and Ki-67 in TNBC suggests that these biomarkers are closely associated with chemotherapy resistance. Monitoring their levels during treatment may help guide more effective clinical strategies for managing TNBC. The findings emphasise the need for personalised therapeutic approaches based on protein expression profiles to improve clinical outcomes for TNBC patients.","PeriodicalId":16175,"journal":{"name":"Journal of Medical Biochemistry","volume":"44 5","pages":"935-944"},"PeriodicalIF":1.5000,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12433301/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medical Biochemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5937/jomb0-56147","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: To assess the predictive value of drug-resistant proteins - serum glutathione S-transferase (GST-â), P-glycoprotein (PGP), P53, Ki-67 - in triple-negative breast cancer (TNBC) and their role in chemotherapy resistance. This systematic review and meta-analysis aimed to explore their clinical relevance for improving TNBC treatment outcomes.

Methods: We systematically searched PubMed, Web of Science, CNKI, WanFang, and VIP databases for studies from 2010 to 2024. Studies meeting predefined inclusion and exclusion criteria were selected. Data extraction and quality assessment were performed by two independent researchers. Meta-analysis was conducted using RevMan 5.3 software.

Results: Seven studies were included, involving 1,772 patients, with 745 TNBC cases and 1,027 non-TNBC cases. Meta-analysis showed that in TNBC compared to non-TNBC, the expression rates of GST-â [O R= 3.41, 95% CI (2.21, 5.25), P< 0.00001], PGP [O R= 1.87, 95% CI (1.17, 2.98), P= 0.008], P53 [O R= 3.65, 95% CI (2.25, 5.91), P< 0.00001], and Ki-67 [O R= 1.19, 95% CI (0.54, 1.84), P= 0.0004] were significantly elevated, indicating higher drug resistance. However, no significant differences were found in Topo I, II, or III expression. Additionally, TNBC patients had poorer disease-free survival (DFS) [O R = 0.30, 95% CI (0.15, 0.59), P=0.0005] and overall survival (OS) [O R=0.17, 95% CI (0.11, 0.28), P<0.00001] compared to non-TNBC patients.

Conclusions: The elevated expression of drug-resistant proteins GST-â, PGP P53, and Ki-67 in TNBC suggests that these biomarkers are closely associated with chemotherapy resistance. Monitoring their levels during treatment may help guide more effective clinical strategies for managing TNBC. The findings emphasise the need for personalised therapeutic approaches based on protein expression profiles to improve clinical outcomes for TNBC patients.

Abstract Image

查看原文本刊更多论文

血清谷胱甘肽s -转移酶（GST- ）、p -糖蛋白（PGP）、P53、KI-67在乳腺癌中的预测价值：一项系统综述和荟萃分析

背景：探讨血清谷胱甘肽s -转移酶（GST- ）、p -糖蛋白（PGP）、P53、Ki-67耐药蛋白在三阴性乳腺癌（TNBC）中的预测价值及其在化疗耐药中的作用。本系统综述和荟萃分析旨在探讨其与改善TNBC治疗结果的临床相关性。方法：系统检索PubMed、Web of Science、CNKI、万方、VIP等数据库2010 - 2024年的研究。选择符合预先确定的纳入和排除标准的研究。数据提取和质量评估由两名独立研究人员进行。采用RevMan 5.3软件进行meta分析。结果：纳入7项研究，共1772例患者，其中TNBC病例745例，非TNBC病例1027例。meta分析显示，与非TNBC相比，TNBC中GST- [O R= 3.41, 95% CI (2.21, 5.25)， P< 0.00001]、PGP [O R= 1.87, 95% CI (1.17, 2.98)， P= 0.008]、P53 [O R= 3.65, 95% CI (2.25, 5.91)， P< 0.00001]、Ki-67 [O R= 1.19, 95% CI (0.54, 1.84)， P= 0.0004]的表达率均显著升高，表明耐药程度较高。然而，Topo I、II或III的表达没有显著差异。此外，TNBC患者的无病生存期（DFS） [O R= 0.30, 95% CI (0.15, 0.59)， P=0.0005]和总生存期（OS） [O R=0.17, 95% CI(0.11, 0.28)]较差。结论：TNBC中耐药蛋白GST- 、PGP、P53和Ki-67的表达升高提示这些生物标志物与化疗耐药密切相关。在治疗期间监测它们的水平可能有助于指导更有效的管理TNBC的临床策略。研究结果强调需要基于蛋白表达谱的个性化治疗方法来改善TNBC患者的临床结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Medical Biochemistry BIOCHEMISTRY & MOLECULAR BIOLOGY-

CiteScore

3.00

自引率

12.00%

发文量

审稿时长

>12 weeks

期刊介绍： The JOURNAL OF MEDICAL BIOCHEMISTRY (J MED BIOCHEM) is the official journal of the Society of Medical Biochemists of Serbia with international peer-review. Papers are independently reviewed by at least two reviewers selected by the Editors as Blind Peer Reviews. The Journal of Medical Biochemistry is published quarterly. The Journal publishes original scientific and specialized articles on all aspects of clinical and medical biochemistry, molecular medicine, clinical hematology and coagulation, clinical immunology and autoimmunity, clinical microbiology, virology, clinical genomics and molecular biology, genetic epidemiology, drug measurement, evaluation of diagnostic markers, new reagents and laboratory equipment, reference materials and methods, reference values, laboratory organization, automation, quality control, clinical metrology, all related scientific disciplines where chemistry, biochemistry, molecular biology and immunochemistry deal with the study of normal and pathologic processes in human beings.